Indoco Remedies

Which are the latest news on Indoco Remedies?

Why is Indoco Remedies Ltd falling/rising?

As of 05-Sep, Indoco Remedies Ltd's stock price is at 262.05, down 4.17% and has underperformed its sector by 3.63%. The stock's long-term outlook is negative due to consistent losses, high debt levels, and low profitability metrics.

As of 05-Sep, Indoco Remedies Ltd's stock price is currently at 262.05, reflecting a decline of 11.4 points or 4.17%. The stock has been experiencing a consecutive fall over the last two days, with a total drop of 4.18% during this period. Additionally, today's performance indicates that it has underperformed its sector by 3.63%. The stock touched an intraday low of Rs 260.9, which represents a decrease of 4.59%.<BR><BR>Despite some positive indicators, such as trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages and an increase in delivery volume by 27.96% against the 5-day average, the overall sentiment appears negative. The company has declared negative results for the last 15 consecutive quarters, which contributes to a weak long-term fundamental strength. Furthermore, the stock has consistently underperformed against benchmarks, generating a return of -4.24% over the past year and showing a significant decline of 45.32% over the last five years.<BR><BR>The financial metrics also highlight concerns, including a high Debt to EBITDA ratio of 7.69 times and a low Return on Equity of 7.83%, indicating low profitability per unit of shareholders' funds. These factors collectively suggest that the stock's decline is driven by ongoing financial struggles and a lack of positive performance indicators, leading to a bearish outlook among investors.

Who are in the management team of Indoco Remedies?

The management team of Indoco Remedies includes Suresh G Kare (Chairman & Wholetime Director), Aditi Kare Panandikar (Managing Director), Sundeep V Bambolkar (Joint Managing Director), and several independent and non-executive directors. They are responsible for guiding the company's strategic direction and operations.

The management team of Indoco Remedies includes the following key members:<BR><BR>1. **Suresh G Kare** - Chairman & Wholetime Director<BR>2. **Aditi Kare Panandikar** - Managing Director<BR>3. **Sundeep V Bambolkar** - Joint Managing Director<BR>4. **Rajiv Kakodkar** - Independent Non-Executive Director<BR>5. **D M Gavaskar** - Independent Non-Executive Director<BR>6. **Vasudha V Kamat** - Independent Non-Executive Director<BR>7. **Abhijit Y Gore** - Independent Non-Executive Director<BR>8. **Anand Nadkarni** - Non-Executive Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Indoco Remedies do?

Indoco Remedies Ltd is a Mumbai-based pharmaceutical company specializing in formulations, contract manufacturing, and research. As of June 2026, it reported net sales of 468 Cr and a net profit of 65 Cr, with a market cap of INR 2,244 Cr.

Overview:<BR>Indoco Remedies Ltd is a Mumbai-based pharmaceutical company focused on formulations, with a presence in contract manufacturing and research, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History:<BR>Indoco Remedies Limited was incorporated on August 23, 1947. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 468 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 65 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 2,244 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.08%<BR>- Debt Equity: 1.13<BR>- Return on Equity: -9.82%<BR>- Price to Book: 2.41<BR><BR>Contact Details:<BR>Address: Indoco House 166 C S T Road, Santacruz (East) Kalina Mumbai Maharashtra : 400098<BR>Tel: 91-022-26541851-55<BR>Email: jagdishs@indoco.com<BR>Website: http://www.indoco.com

Who are the peers of the Indoco Remedies?

Indoco Remedies' peers include Hikal, Fredun Pharma, Panacea Biotec, Venus Remedies, Windlas Biotech, Shukra Pharma, Hester Bios, Beta Drugs Ltd, and Sakar Healthcare. Fredun Pharma shows the best performance in management risk and growth, while Indoco Remedies has a 1-year return of -8.62%.

Peers: The peers of Indoco Remedies are Hikal, Fredun Pharma, Panacea Biotec, Venus Remedies, Windlas Biotech, Shukra Pharma, Hester Bios, Beta Drugs Ltd, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fredun Pharma and Shukra Pharma, while Average management risk is found at Hikal, Indoco Remedies, Venus Remedies, Windlas Biotech, Hester Bios, Beta Drugs Ltd, and Sakar Healthcare, and the rest. Growth is Excellent at Fredun Pharma and Shukra Pharma, Good at Venus Remedies, Average at Beta Drugs Ltd, and Below Average at Hikal, Panacea Biotec, Indoco Remedies, Windlas Biotech, Hester Bios, and the rest. Capital Structure is Excellent at Venus Remedies and Beta Drugs Ltd, Average at Sakar Healthcare, and Below Average at Hikal, Fredun Pharma, Panacea Biotec, Indoco Remedies, Windlas Biotech, Hester Bios, and the rest.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 279.00%, while Hikal has the lowest at -20.90%. Indoco Remedies' 1-year return is -8.62%, which is higher than Hikal's but lower than Fredun Pharma's. Additionally, there are no peers with a negative six-month return.

How big is Indoco Remedies?

As of 31st August, Indoco Remedies Ltd has a market capitalization of 2,244.00 Cr, with net sales of 1,873.14 Cr and a net profit of 5.63 Cr reported in the latest four quarters.

As of 31st August, Indoco Remedies Ltd has a market capitalization of 2,244.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Indoco Remedies reported net sales of 1,873.14 Cr and a net profit of 5.63 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 939.28 Cr and total assets valued at 2,593.27 Cr.

Should I buy, sell or hold Indoco Remedies Ltd?

Are Indoco Remedies Ltd latest results good or bad?

Indoco Remedies Ltd's latest results show a return to profitability with a net profit of ₹64.99 crores and a 6.33% revenue growth, but concerns about declining sequential revenue, high debt-to-equity ratio of 1.16x, and rising interest costs suggest caution for investors.

Indoco Remedies Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹64.99 crores for Q1 FY27, marking a significant turnaround from a loss of ₹35.79 crores in the same quarter last year. This is a positive indicator of profitability, especially as it reflects a dramatic improvement in operational performance.<BR><BR>Additionally, the company achieved a year-on-year revenue growth of 6.33%, reaching ₹467.50 crores, and improved its operating margin to 8.80% from 4.07% a year ago. These metrics suggest some operational recovery and better cost management.<BR><BR>However, there are significant concerns that temper this positive outlook. The sequential comparison shows a decline in revenue by 1.71% from the previous quarter, which raises questions about the sustainability of the profit increase. Furthermore, the company's debt-to-equity ratio has reached a concerning 1.16x, the highest in its recent history, indicating a precarious financial position. The rising interest costs, which grew by 47.83% over the last six months, further complicate the situation.<BR><BR>Overall, while the return to profitability and revenue growth are encouraging, the underlying issues related to debt and operational efficiency suggest that the results may not be as solid as they appear at first glance. Investors should be cautious and consider the broader financial context when evaluating Indoco Remedies Ltd's performance.

When is the next results date for Indoco Remedies Ltd?

The next results date for Indoco Remedies Ltd is 07 May 2026.

The next results date for Indoco Remedies Ltd is scheduled for 07 May 2026.

Is Indoco Remedies technically bullish or bearish?

As of December 2, 2025, Indoco Remedies exhibits a neutral technical trend with mixed signals, showing a mildly bearish outlook on weekly indicators and a lack of clear direction overall.

As of 2 December 2025, the technical trend for Indoco Remedies has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are bearish, while the monthly MACD and KST are mildly bullish, indicating a lack of clear direction. The Bollinger Bands are mildly bearish on both weekly and monthly charts, reinforcing the sideways trend. Daily moving averages show a mildly bullish stance, but this is countered by the overall bearish signals from the weekly indicators. The Dow Theory indicates a mildly bearish outlook on the weekly timeframe, while the monthly shows no trend. Overall, the strength of the current neutral stance is weak, driven primarily by conflicting signals across various indicators.

How has been the historical performance of Indoco Remedies?

Indoco Remedies has experienced fluctuating financial performance, with net sales decreasing to 1,664.92 Cr in March 2025 from 1,817.29 Cr in March 2024, and a significant drop in operating profit leading to a profit before tax of -74.37 Cr. Despite an increase in total assets, the company faces challenges in profitability, as reflected by a profit after tax of -77.95 Cr in March 2025.

Answer:<BR>The historical performance of Indoco Remedies shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Indoco Remedies reported net sales of 1,664.92 Cr in March 2025, a decrease from 1,817.29 Cr in March 2024, but an increase from 1,668.61 Cr in March 2023. The total operating income followed a similar pattern, with a total of 1,664.92 Cr in March 2025 compared to 1,817.29 Cr in the previous year. The total expenditure, excluding depreciation, was 1,565.66 Cr in March 2025, slightly down from 1,572.98 Cr in March 2024. Operating profit (PBDIT) decreased significantly to 99.26 Cr in March 2025 from 244.31 Cr in March 2024, leading to a profit before tax of -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax also fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total assets increased to 2,429.91 Cr in March 2025 from 2,144.73 Cr in March 2024, while total liabilities rose to 2,429.91 Cr from 2,144.73 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 94.00 Cr in March 2025 from 155.00 Cr in March 2024, and the closing cash and cash equivalents were reported at 12.00 Cr in March 2025, down from 14.00 Cr in March 2024. Overall, the financial performance of Indoco Remedies reflects challenges in profitability despite growth in sales and total assets.

Is Indoco Remedies overvalued or undervalued?

As of May 23, 2025, Indoco Remedies is considered overvalued and risky due to troubling financial ratios, including a PE ratio of -33.83 and negative returns year-to-date, especially when compared to more profitable peers like Sun Pharma and Cipla.

As of 23 May 2025, the valuation grade for Indoco Remedies has moved from attractive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued, given its troubling financial ratios, including a PE ratio of -33.83, an EV to EBIT ratio of -240.53, and a ROE of -7.31%. These figures suggest that the company is struggling to generate profits and is not performing well compared to its peers.<BR><BR>In comparison to industry peers, Indoco Remedies stands out unfavorably; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights the challenges Indoco Remedies faces in the current market environment. Additionally, while the stock has recently outperformed the Sensex over the past week and month, its year-to-date and one-year returns remain negative, further reinforcing the notion that the stock is overvalued in light of its financial performance.

Who are the top shareholders of the Indoco Remedies?

The top shareholders of Indoco Remedies include Spa Holdings Pvt Ltd with 19.88%, mutual funds holding 18.52%, and individual investors owning 15.99%. Notably, Nippon Life India Trustee Ltd is the largest public shareholder with 4.8%.

The top shareholders of Indoco Remedies include a mix of promoters and institutional investors. The largest promoter is Spa Holdings Pvt Ltd, which holds 19.88% of the shares. The promoters collectively hold a significant portion of the company, with no pledged promoter holdings reported. <BR><BR>In terms of institutional investors, mutual funds hold 18.52% of the shares through 8 different schemes, while foreign institutional investors (FIIs) have a smaller stake of 1.24% across 39 entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund and holds 4.8%. Additionally, individual investors collectively own 15.99% of the company.

What is the bonus history of the Indoco Remedies?

Indoco Remedies issued a bonus share in a 1:2 ratio on May 17, 2012, with a record date of May 19, 2012. This is the most recent bonus action recorded for the company.

Indoco Remedies has a bonus history that includes a notable issue announced on May 17, 2012. The company issued a bonus in the ratio of 1:2, meaning that for every two shares held, shareholders received one additional share. The record date for this bonus was May 19, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Indoco Remedies or need further details, feel free to ask!

Has Indoco Remedies declared dividend?

Indoco Remedies Ltd has declared a 75% dividend, amounting to ₹1.5 per share, with an ex-date of September 19, 2024. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns in the short term.

Indoco Remedies Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.54%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.9%, with a dividend return of 0%, resulting in a total return of -14.9%.<BR><BR>Over the past year, the price return was -12.95%, the dividend return was 0.46%, leading to a total return of -12.49%.<BR><BR>In the 2-year period, the price return was -16.99%, the dividend return was 1.13%, culminating in a total return of -15.86%.<BR><BR>For the 3-year period, the price return was -27.73%, with a dividend return of 1.43%, resulting in a total return of -26.3%.<BR><BR>In the last 4 years, the price return was -29.74%, the dividend return was 1.73%, which led to a total return of -28.01%.<BR><BR>Over the 5-year period, the price return was 22.57%, with a dividend return of 3.36%, resulting in a total return of 25.93%.<BR><BR>Overall, while Indoco Remedies has declared a dividend, the total returns over various periods indicate significant price declines, particularly in the shorter terms, suggesting challenges in the company's stock performance despite the dividend declaration.